Neuroscience medicines
WE AIM TO STRENGTHEN OUR NEUROSCIENCE POSITION THROUGH FURTHER GROWTH OF THE SEROQUEL FRANCHISE, BRINGING NEW VALUE TO PATIENTS AND DOCTORS WITH SEROQUEL XR AND BY THE SUCCESSFUL INTRODUCTION OF A RANGE OF LIFE-CHANGING MEDICINES AIMING TO MEET SIGNIFICANT MEDICAL NEED IN PAIN CONTROL, NEUROLOGY AND PSYCHIATRY.
2007 IN BRIEF
- Seroquel sales up 15% to over $4 billion.
- Seroquel XR major depressive disorder and generalised anxiety disorder clinical study data presented for the first time. US and EU regulatory submissions planned in 2008.
- Seroquel XR approved in nine countries, including the US, and progressed through the mutual recognition procedure in the EU, for acute and maintenance treatment of schizophrenia.
- US regulatory submissions for Seroquel XR for the treatment of bipolar depression and bipolar mania.
- AZD3480 entered Phase IIb testing in Alzheimer’s disease and cognitive disorders in schizophrenia.
- Patent infringement actions commenced against two generic drug manufacturers in the US following abbreviated new drug applications relating to Seroquel.
- Numerous personal injury actions in the US and Canada involving Seroquel being defended vigorously.
MARKETED PRODUCTS1
Seroquel (quetiapine fumarate) is an atypical anti-psychotic drug. It is approved for the treatment of schizophrenia, bipolar mania and bipolar depression. Its overall clinical efficacy and tolerability profile helped make it the leading atypical anti-psychotic in the US.
Zomig (zolmitriptan) is for the treatment of migraine with or without aura.
Diprivan (propofol), an intravenous general anaesthetic, is used in the induction and maintenance of anaesthesia, light sedation for diagnostic procedures and for intensive care sedation.
Naropin (ropivacaine), with its safety and mobility profile, is the world’s best-selling, long-acting local anaesthetic, replacing the previous standard treatment of bupivacaine.
Xylocaine (lidocaine) continues to be the world’s most widely used short-acting local anaesthetic after more than 50 years on the market.
1In 2006, we sold our range of US branded anaesthetics and analgesic products to Abraxis BioScience, Inc.. These included Xylocaine™, Polocaine™, Naropin™, Nesacaine™, Sensorcaine™, Astramorph™, EMLA Cream™and Diprivan™.
